Wednesday, April 23, 2008

Two Healthcare Stock Reports

Illumina (ILMN) is rocketing up again +11% early today on a very good earnings report; this is one of those conundrum stocks - very expensive but seemingly destined to remain so. And as they keep raising guidance, they get a bit less expensive, I suppose. Still at 50x forward estimates! I continue to wait for a meaningful pullback that never really seems to happen. My position is woefully underweight. But I do love stocks like this that perform under the radar of the hordes of momentum traders and ambulance chasers. This is how fertilizer used to be 8-10 months ago ;)
  • Illumina Inc (ILMN), a maker of products used in genetic research, posted first-quarter results and provided 2008 outlook that beat market expectations significantly
  • Excluding items, Illumina earned 37 cents a share this quarter compared with 22 cents a share a year ago. Revenue rose 69 percent to $121.9 million.
  • Analysts on average had expected earnings of 24 cents a share, before special items, on revenue of $115.3 million, according to Reuters Estimates.
  • The San Diego-based company expects 2008 earnings of $1.55 to $1.68 a share, excluding items, on revenue of $515 million to $535 million. Analysts were expecting a profit of $1.18 a share, before special items, on revenue of $519.9 million.
Pharmaceutical Product Development (PPDI) is the first of a slew of the contract research outsource firms to report - they put out a solid number, nothing spectacular, but looking at the charts it seemed people were braced for the worst [Contract Research Organizatiosn Weak Again]- so hearing nothing of the sort was enough to push this stock up 7% this AM. Peer Parexel International (PRXL) reports after the bell and appears to be up 7% in sympathy. This is not a sexy group, but solid growers.
  • Contract research company Pharmaceutical Product Development Inc. said Tuesday its first-quarter profit fell 4 percent on a series of investment charges and writeoffs related to the failed drug candidate SinuNase.
  • The company earned $40.1 million, or 33 cents per share, compared with profit of $42 million, or 35 cents per share, during the same period a year prior. Excluding charges, the company said it earned 44 cents per share. Analysts polled by Thomson Financial expected profit of 43 cents per share.
  • Revenue rose 19 percent to $396.2 million from $332.3 million. Analysts expected revenue to reach $396.3 million.
I continue to favor these types of names over drug companies with FDA risk, or even healthcare organizations - "safe" stocks like UnitedHealth Group (UNH) are down 40% YTD. A lot of investors must be cursing the "safety" of this group.

Long Illumina in fund; no personal position

Disclaimer: The opinions listed on this blog are for educational purpose only. You should do your own research before making any decisions.
This blog, its affiliates, partners or authors are not responsible or liable for any misstatements and/or losses you might sustain from the content provided.

Copyright @2012